





Supplementary Fig. 1 Effect of saline, bleomycin (BLM) and bleomycin+nintedanib (BLM+NINT) on mouse body weight.

Each line represents changes in mean body weight, on the indicated days, expressed as a percentage of the mean weight for each group, measured on the first day of the experiment. Data points are means \pm S.E.M. (n=8) for each group. Asterisks indicate statistical significance of each group vs. BLM at each timepoint (**P < 0.01; two-way ANOVA followed by Dunnett's post hoc multiple comparison test for continuous data).



Supplementary Fig. 2 Inflammatory cell concentration in the bronchoalveolar fluid (BALF) of saline, bleomycin (BLM) and bleomycin+nintedanib (BLM+NINT)-treated mice. Concentration of (A) white blood cells (WBC), (B) total macrophages, (C) lymphocytes and (D) neutrophils in the BALF. Data are shown as mean values \pm S.E.M. for 8 mice per group. Asterisks indicate significant statistical differences in comparison with BLM group (* $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$, ANOVA followed by Dunnett's test). The percentages on the BLM+NINT bars represent the inhibition effect of the treatment compared to BLM.